ARCT
Price
$16.71
Change
-$0.30 (-1.76%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
461.9M
64 days until earnings call
NVAX
Price
$7.56
Change
+$0.09 (+1.20%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
1.21B
64 days until earnings call
Interact to see
Advertisement

ARCT vs NVAX

Header iconARCT vs NVAX Comparison
Open Charts ARCT vs NVAXBanner chart's image
Arcturus Therapeutics Holdings
Price$16.71
Change-$0.30 (-1.76%)
Volume$7.64K
Capitalization461.9M
Novavax
Price$7.56
Change+$0.09 (+1.20%)
Volume$82.76K
Capitalization1.21B
ARCT vs NVAX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. NVAX commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and NVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ARCT: $17.01 vs. NVAX: $7.47)
Brand notoriety: ARCT: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 91% vs. NVAX: 93%
Market capitalization -- ARCT: $461.9M vs. NVAX: $1.21B
ARCT [@Biotechnology] is valued at $461.9M. NVAX’s [@Biotechnology] market capitalization is $1.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, ARCT is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 5 bearish.
  • NVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than NVAX.

Price Growth

ARCT (@Biotechnology) experienced а -8.10% price change this week, while NVAX (@Biotechnology) price change was -4.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

NVAX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.21B) has a higher market cap than ARCT($462M). ARCT YTD gains are higher at: 0.236 vs. NVAX (-7.090). NVAX has higher annual earnings (EBITDA): 496M vs. ARCT (-54.54M). NVAX has more cash in the bank: 612M vs. ARCT (196M). ARCT has less debt than NVAX: ARCT (27M) vs NVAX (228M). NVAX has higher revenues than ARCT: NVAX (1.08B) vs ARCT (110M).
ARCTNVAXARCT / NVAX
Capitalization462M1.21B38%
EBITDA-54.54M496M-11%
Gain YTD0.236-7.090-3%
P/E RatioN/A3.36-
Revenue110M1.08B10%
Total Cash196M612M32%
Total Debt27M228M12%
FUNDAMENTALS RATINGS
ARCT vs NVAX: Fundamental Ratings
ARCT
NVAX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4260
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVAX (81) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than NVAX’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NVAX’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NVAX’s over the last 12 months.

ARCT's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as NVAX (60) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that NVAX’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTNVAX
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
85%
Momentum
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 5 days ago
88%
MACD
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
83%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PETZX14.870.06
+0.41%
Gabelli Pet Parents'™
THOFX46.020.11
+0.24%
Thornburg Global Opportunities R5
FRINX12.21N/A
N/A
Fidelity Advisor Real Estate Income A
MNBWX20.66-0.06
-0.29%
Manning & Napier Pro-Blend Extnd Term W
DHIIX20.14-0.08
-0.40%
Diamond Hill International I

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RGNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-1.68%
RGNX - ARCT
51%
Loosely correlated
-0.89%
CLDX - ARCT
49%
Loosely correlated
-1.34%
RXRX - ARCT
46%
Loosely correlated
-3.39%
MRNA - ARCT
46%
Loosely correlated
-1.55%
MGNX - ARCT
46%
Loosely correlated
+4.12%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.45%
MRNA - NVAX
48%
Loosely correlated
-1.55%
BNTX - NVAX
43%
Loosely correlated
-1.89%
ARCT - NVAX
40%
Loosely correlated
-1.68%
XNCR - NVAX
37%
Loosely correlated
+0.99%
CRSP - NVAX
36%
Loosely correlated
-2.30%
More